Jul 31, 2026 · 5 min
Amazon surges on cloud growth while Apple slips on supply constraints
Apple Slides, Amazon Surges, Replimune Soars as FDA Panel Supports Drug
The contrasting fortunes of Apple and Amazon highlight how cloud demand and supply chain resilience are dividing the tech sector's biggest players.
- 1Apple shares fell due to supply chain constraints, currency fluctuations, and weaker revenue forecasts.
- 2Amazon stock surged on accelerating cloud-computing revenue and strong AWS performance.
- 3Replimune shares skyrocketed following positive backing from an FDA advisory panel for its melanoma therapy.
Don't miss
Avalon Purnell breaks down how hedge fund managers trade around core positions like Apple during earnings misses.
The brief
Tech earnings season delivers a split verdict as Apple faces headwinds from supply chain constraints and currency fluctuations while Amazon surges on accelerating cloud-computing revenue.
Apple's stock slipped following its third-quarter results, driven by weaker-than-expected revenue forecasts and notable misses in services and China-based revenue.
Hedge fund managers are actively trading around core positions like Apple to navigate these headwinds, even as long-term growth prospects remain a central debate.
Amazon countered the tech drag, with its shares surging on the back of accelerating cloud-computing revenue and strong performance from AWS.
In healthcare, biotech firm Replimune saw its shares skyrocket after receiving positive backing from an FDA advisory panel for its experimental melanoma therapy.
What was said on this episode
5 statements · 2 positive · 2 negative · 1 neutral
Apple forecast weaker-than-expected revenue growth.
“It also forecasts revenue growth that was a little bit weaker than expected”
Listen at 1:14
Apple’s results are underwhelming because key segments are weak.
“the results are underwhelming given the weakness in those segments”
Listen at 1:36
Hedge fund managers buy core positions when cheap and sell near-term when expensive.
“When it got a little cheap, you buy a little bit more, got a little bit above where you guys thought it should be. Near term you sell it”
Listen at 2:03
AWS delivered accelerating growth, higher profitability, and an improved backlog.
“AWS delivered accelerating growth, surging profitability and a better backlog”
Listen at 2:35
Analysts say the FDA’s imminent decision could be positive for Replimune.
“the FDA's decision, which could come as soon as later today, some analysts say could actually end up being positive”
Listen at 3:21
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Featuring
Apple Inc.
Amazon.com, Inc.
Bloomberg L.P.Books & mentions
Listen to the full episode and explore every guest, topic, and moment on PodLume.